Resistance to Targeted Anti-Cancer Therapeutics

Prosperi, Jenifer R.

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.

Details

Published by: Springer

Publication Date: 2017-12-13

Format: Hardcover

ISBN-13: 9783319701417

DOI: 10.1007/978-3-319-70142-4

Dimensions: 235cm x155cm

Pages: 184